Burfiralimab
CAS No. 2460809-80-5
Burfiralimab( —— )
Catalog No. M36776 CAS No. 2460809-80-5
Burfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 299 | Get Quote |
|
| 5MG | 471 | Get Quote |
|
| 10MG | 708 | Get Quote |
|
| 25MG | 1030 | Get Quote |
|
| 50MG | 1371 | Get Quote |
|
| 100MG | 1782 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBurfiralimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionBurfiralimab (hzVSF-v13) is a monoclonal immunoglobulin (IgG4) targeted against waveform proteins, exhibiting anti-HBV properties and potential applications in rheumatoid arthritis research.
-
DescriptionBurfiralimab (hzVSF-v13) is a monoclonal IgG4 antibody against vimentin expressed on the surface of virus-infected cells, with broad-spectrum antiviral activity and anti-inflammatory effects against virus-induced inflammation. Burfiralimab can be used in severe COVID-19 studies.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2460809-80-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Prasenohadi Prasenohadi, et al. Double-Blind, Randomized, Placebo-Controlled Study on hzVSF-v13, a Novel Anti-Vimentin Monoclonal Antibody Drug as Add-on Standard of Care in the Management of Patients with Moderate to Severe COVID-19. J Clin Med. 2022 May 24;11(11):2961.?
molnova catalog
related products
-
Ibandronic acid
Ibandronic acid is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
-
Canocapavir
Canocapavir (ZM-H1505R) is a novel orally available HBV coat protein modulator with antiviral activity that induces conformational changes in the linker region of the HBV core protein, and can be used for the treatment of hepatitis B virus.
-
Antiviral agent
Antiviral agent is thiazolidin-4-one with anti-hepatitis B activity
Cart
sales@molnova.com